Medical device innovation: Pylarify injection and Pylarify AI
Lantheus Holdings’ Pylarify injection is a fluorinated small molecule PSMA-targeted PET imaging agent that allows for the visualization of lymph nodes, bone and soft tissue. It is used to determine the presence or absence of recurrent or metastatic prostate cancer. The Pylarify AI system is a deep learning algorithm that allows physicians to perform standardized quantitative assessments of PSMA/PET/CT images.
Lantheus Holdings launched the device software in November 2021. It can be deployed as a secure web cloud application or within a secure firewall of the facility on a local server. It is intended for use by healthcare workers for acceptance, transfer, storage, image display, manipulation, quantification and reporting of digital medical images.